Literature DB >> 6699841

Renal papillary necrosis due to naproxen.

R J Caruana, E L Semble.   

Abstract

A 31-year-old man with rheumatoid arthritis, who had previously been treated with sulindac, fenoprofen calcium, high dose salicylates and gold salts, developed renal papillary necrosis (RPN) 4 months after institution of naproxen therapy. No other factor predisposing to RPN could be discovered. Sulindac was substituted for naproxen and no further adverse renal effects occurred over the next 12 months. We review previous reports linking RPN to antiinflammatory drug use and discuss possible advantages of sulindac in patients who have experienced renal toxicity from other antiinflammatory agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6699841

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  3 in total

Review 1.  Naproxen. A reappraisal of its pharmacology, and therapeutic use in rheumatic diseases and pain states.

Authors:  P A Todd; S P Clissold
Journal:  Drugs       Date:  1990-07       Impact factor: 9.546

Review 2.  Renal papillary necrosis induced by naproxen.

Authors:  Larisa Kovacevic; Jay Bernstein; Rudolph P Valentini; Abubakr Imam; Neena Gupta; Tej K Mattoo
Journal:  Pediatr Nephrol       Date:  2003-05-28       Impact factor: 3.714

Review 3.  Nonsteroidal Anti-Inflammatory Drugs and the Kidney.

Authors:  Walter H Hörl
Journal:  Pharmaceuticals (Basel)       Date:  2010-07-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.